tradingkey.logo

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

ReutersJun 23, 2025 1:04 PM

- Revolution Medicines Inc RVMD.O:

  • REVOLUTION MEDICINES ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION FOR DARAXONRASIB IN PREVIOUSLY TREATED METASTATIC PANCREATIC CANCER WITH KRAS G12 MUTATIONS

  • REVOLUTION MEDICINES INC - DESIGNATION BASED ON DATA FROM PHASE 1 TRIAL

  • REVOLUTION MEDICINES INC - PHASE 3 STUDY OF DARAXONRASIB EXPECTED TO COMPLETE ENROLLMENT THIS YEAR

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI